NACDS applauds decision to not pursue border adjustment tax
ARLINGTON, Va. — The National Association of Chain Drug Stores is commending congressional leaders and the White House for setting aside consideration of a border adjustment tax — a decision reached late this week.
“From the beginning of this debate, NACDS aligned with Americans for Affordable Products given our strongest of concerns about the border adjustment tax. We have urged our nation’s leaders to set aside the BAT from a health-and-wellness perspective; from a total-store perspective; from a consumer perspective; from an employee perspective; and from an employer perspective. From all of these viewpoints, we commend congressional leaders and the White House for listening to the concerns raised by NACDS, by Americans for Affordable Products and by many others, and for deciding to not pursue the BAT,” said NACDS president and CEO Steven C. Anderson, IOM, CAE.
Throughout the year, NACDS articulated its position on the border adjustment tax in outreach to the Senate Finance Committee and to the House Ways and Means Committee, as well as through congressional meetings conducted by NACDS board of director members.
For its part, NACDS supports the “Made in the U.S.A.” movement, as demonstrated by the success of programs to call attention to qualifying products at the NACDS Total Store Expo trade show and strategic exchange.
The 2017 NACDS Total Store Expo will be held August 19-22 in San Diego.
NCPA Innovation Center announces mental health first aid training scholarship winners
ALEXANDRIA, Va. — The NCPA Innovation Center today announced three mental health first aid training scholarships winners.
Clark Bishop, PharmD, co-owner of Hutton Pharmacy in Blackwell, Okla.; Talia Puzantian, PharmD, BCPP, associate professor at the Keck Graduate Institute School of Pharmacy in Claremont, Calif.; and Thomas Smith, PharmD, BCPP, assistant professor of pharmacy practice at Manchester University in Fort Wayne, Ind., were awarded the scholarships as part of a larger NCPA Innovation Center grant from the Community Pharmacy Foundation. Bishop, Puzantian and Smith will complete the weeklong instructor training this fall and commit to training community pharmacists and their teams in mental health first aid.
“The NCPA Innovation Center is dedicated to helping accelerate the community pharmacist’s role in the healthcare team and their training in mental health first aid is a great example of this trend,” said NCPA Innovation Center board member Tripp Logan, PharmD, co-owner of L&S Pharmacy in Charleston, Mo. “I recently sent two of my pharmacists and four technicians to mental health first aid training and was impressed with their reactions, especially those of the technicians. The training will be even more effective for pharmacy teams when taught by pharmacists using pharmacy-specific cases.”
The eight-hour live education program teaches attendees how to identify, understand and respond to signs of mental illness and substance use disorders. As pharmacy team members are often on the front line of patient care, they interact with patients who face these disorders on a regular basis, but may be underprepared to effectively care for them. Utilizing case examples and role play, the training session emphasizes how pharmacists can apply what they learn to real-life scenarios.
A second component of the CPF project provided funding to develop pharmacy-specific cases for the training. These cases will be used during the program led by these scholarship award winners as well as any other certified mental health first aid instructor.
FDA green-lights Fycompa for treatment of partial-onset seizures
WOODCLIFF LAKE, N.J. — The U.S. Food and Drug Administration this week approved Eisai’s Fycompa (perampanel) CIII as monotherapy use for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older.
Fycompa is also approved for adjunctive use for partial-onset seizures and primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. It is the first antiepileptic drug to apply FDA's regulatory pathway of extrapolation for monotherapy use. The FDA had proposed using this pathway to get monotherapy options to patients sooner in a general advice letter dated Sept. 13, 2016.
"This approval is good news for the epilepsy community because it means that more physicians and patients will have access to a single agent option for partial-onset seizures," said Jacqueline A. French, MD, professor of neurology in the epilepsy division at NYU Langone Medical Center, chief scientific officer for the Epilepsy Foundation and director of the Epilepsy Study Consortium, a nonprofit organization devoted to speeding new therapies through the development process and into the clinic. "To date, conducting clinical trials with single agents in epilepsy has been problematic. Now, with this change in the regulatory pathway, we have a safe and efficient process for quicker access to single agent therapies for partial-onset seizures."
Fycompa was initially approved for adjunctive use in partial-onset seizures in 2012 and has been approved in 55 countries worldwide. To date, more than 100,000 patients have been treated with Fycompa. An oral suspension formulation was also approved in 2016. In the three initial adjunctive pivotal clinical trials in patients with partial-onset seizures, results showed improvement in seizure control in patients taking Fycompa compared with those taking placebo.